Article Information
History
- December 25, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Raburn Mallory, M.D.*,
- Neil Formica, M.B.B.S.,
- Susan Pfeiffer, P.A-C.,
- Bethanie Wilkinson, Ph.D.,
- Alex Marcheschi, Pharm.D.,
- Gary Albert, M.S.,
- Heather McFall, M.S.,
- Michelle Robinson, M.P.H.,
- Joyce S. Plested, Ph.D.,
- Mingzhu Zhu, Ph.D.,
- Shane Cloney-Clark, B.Sc.,
- Bin Zhou, Ph.D.,
- Gordon Chau, M.S.,
- Andreana Robertson, M.S.,
- Sonia Maciejewski, Ph.D.,
- Gale Smith, Ph.D.,
- Nita Patel, Ph.D.,
- Gregory M. Glenn, M.D.,
- Filip Dubovsky, M.D.,
- for the Novavax Inc. 2019nCoV-101 Study Group
- ↵*Contact information for corresponding author: Raburn Mallory at Novavax, 21 Firstfield Rd., Gaithersburg, MD, 20878, or RMallory{at}novavax.com.
Posted December 25, 2021.
Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial
